A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
about
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase I dose-escalation stud ...... ts with advanced malignancies.
@en
A phase I dose-escalation stud ...... ts with advanced malignancies.
@nl
type
label
A phase I dose-escalation stud ...... ts with advanced malignancies.
@en
A phase I dose-escalation stud ...... ts with advanced malignancies.
@nl
prefLabel
A phase I dose-escalation stud ...... ts with advanced malignancies.
@en
A phase I dose-escalation stud ...... ts with advanced malignancies.
@nl
P2093
P2860
P1476
A phase I dose-escalation stud ...... ts with advanced malignancies.
@en
P2093
Hideaki Takahashi
Hironobu Ohmatsu
Kazunori Uenaka
Kellie Turner
Kiyotaka Yoh
Sotaro Enatsu
Takashi Kojima
Takashi Nakamura
Volker Wacheck
Yoshitaka Zenke
P2860
P2888
P304
P356
10.1007/S10637-016-0370-7
P577
2016-09-01T00:00:00Z